Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC (AZN) generates a steady flow of news driven by its global biopharmaceutical activities in Oncology, Rare Diseases and BioPharmaceuticals. Company announcements frequently cover clinical trial milestones, regulatory decisions, manufacturing investments and strategic collaborations, offering investors and healthcare professionals insight into how its pipeline and marketed medicines are evolving.
Recent news highlights include multiple updates on Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan), two antibody drug conjugates jointly developed with Daiichi Sankyo. These stories describe new Phase 3 trials, Breakthrough Therapy Designations, and approvals in indications such as HER2-positive early breast cancer, metastatic breast cancer, HER2-expressing endometrial cancer and HER2-expressing ovarian cancer, as well as TROP2-directed approaches in lung and breast cancer.
News items also cover immuno-oncology developments with Imfinzi (durvalumab), including perioperative regimens for gastric and gastroesophageal junction cancers based on the MATTERHORN trial, and broader use in gastrointestinal and thoracic malignancies. In Rare Diseases and immunology, AstraZeneca reports on approvals for Koselugo in adult NF1-associated plexiform neurofibromas and on expanded administration options for Saphnelo in systemic lupus erythematosus.
Beyond clinical and regulatory updates, AstraZeneca’s news feed includes information on large-scale manufacturing investments in the United States, such as expansion of biologics facilities in Maryland, and technology partnerships like the selection of Salesforce’s Agentforce Life Sciences platform for AI-powered customer engagement. Visitors to this AZN news page can review these developments to understand how AstraZeneca’s pipeline, approvals and infrastructure may influence its long-term strategic direction.
AstraZeneca and Daiichi Sankyo's ENHERTU® has received acceptance for its supplemental Biologics License Application and has been granted Priority Review by the FDA for treating HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The FDA's action date is set for Q1 2021. This reflects critical advancements in treatment options, as current approved HER2-directed therapies are lacking for patients with poor prognosis after initial anti-HER2 treatment. The sBLA is based on the DESTINY-Gastric01 trial, showing significant improvements in patient outcomes.
AstraZeneca announced new findings from the DAPA-CKD Phase III trial indicating that FARXIGA (dapagliflozin) significantly reduces the risk of worsening kidney function and cardiovascular or renal death in patients with chronic kidney disease (CKD), regardless of its cause. The study showed a relative risk reduction of 37% for diabetic kidney disease and 25% for hypertension, among others. FARXIGA also demonstrated a decrease in all-cause mortality. These results support FARXIGA's potential to change CKD treatment standards. The data were presented at the American Society of Nephrology Kidney Week 2020.
AstraZeneca, alongside Scientific American Custom Media, revealed the winners of the second annual Cancer Community (C2) Awards, celebrating grassroots organizations enhancing cancer care. This year’s event received nominations from 31 states. The C2 Awards feature four categories, awarding $50,000 to each winner to support non-profits in the cancer community. Significant honorees include Lynette Bonar, who opened the first cancer facility on a Navajo reservation, and Dr. Lincoln D. Nadauld, recognized for his advancements in precision medicine that doubled patient survival rates.
AstraZeneca's TAGRISSO® (osimertinib) has received acceptance for its supplemental New Drug Application and Priority Review by the FDA for treating early-stage EGFR-mutated non-small cell lung cancer post-surgery. The FDA's expedited review highlights TAGRISSO's potential to significantly improve disease-free survival rates, particularly in patients with Stage II and IIIA disease, based on results from the ADAURA Phase III trial. Approximately 30% of NSCLC patients could benefit from this treatment, as many experience recurrence despite surgery.
AstraZeneca's FARXIGA® (dapagliflozin) has received Breakthrough Therapy Designation (BTD) from the FDA for treating chronic kidney disease (CKD) in patients with and without type 2 diabetes. This designation is aimed at accelerating the development of treatments for serious conditions with unmet medical needs. Clinical trial results showed that FARXIGA reduced the risk of worsening renal function or death from cardiovascular causes by 39%. The drug is crucial as approximately 37 million people in the US have CKD.
Ascentage Pharma has announced a clinical collaboration with Acerta Pharma, a part of AstraZeneca (AZN), to sponsor a Phase Ib/II trial studying the combination of Ascentage's APG-2575 (a Bcl-2 inhibitor) and Acerta's CALQUENCE® (acalabrutinib, a BTK inhibitor) for treating relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This multicenter study has begun in the US and will expand to Europe and Australia, targeting efficacy and safety to explore potential synergistic effects and improved treatment options for patients.